{"id":951948,"date":"2026-04-16T07:11:35","date_gmt":"2026-04-16T11:11:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/"},"modified":"2026-04-16T07:11:35","modified_gmt":"2026-04-16T11:11:35","slug":"eton-pharmaceuticals-announces-cfo-succession-plan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/","title":{"rendered":"Eton Pharmaceuticals Announces CFO Succession Plan"},"content":{"rendered":"

\nExperienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st
\n<\/h2>\n
\n

DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the \u201cCompany\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith \u201cJudy\u201d M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026.<\/p>\n

The Company\u2019s current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement with Eton.<\/p>\n

\u201cWe are pleased to welcome Judy to Eton. She brings deep experience leading finance for growth-focused pharmaceutical companies and will be a valuable addition as we enter our next phase of growth,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cOn behalf of the entire Company, I want to thank James for his contributions and dedication over the last four years. He provided exceptional leadership to our finance department through a period of rapid growth and numerous product integrations.\u201d<\/p>\n

\u201cEton\u2019s unique model and impressive execution have set it apart in the industry. I am excited to be joining the organization at such a pivotal time, and I look forward to partnering with the team on the mission to build the largest rare disease portfolio in the United States,\u201d said Judy Matthews, Executive Vice President, Accounting and Finance.<\/p>\n

Ms. Matthews brings more than 25 years of finance leadership experience, including significant experience at fast-growing pharmaceutical and biotechnology companies. Prior to joining Eton, she served as Chief Financial Officer of Iterum Therapeutics plc from 2015 to 2026. Previously, she was Vice President of Finance at Durata Therapeutics until its acquisition by Actavis plc.<\/p>\n

Ms. Matthews holds a B.A. in Accounting from the University of Illinois at Urbana-Champaign and a Master of Management in Finance and Marketing from the Kellogg School of Management at Northwestern University.<\/p>\n

\n About<\/strong>
\n \u00a0<\/strong>
\n Eton <\/strong>
\n Pharmaceuticals<\/strong>\n <\/p>\n

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVITM<\/sup>, INCRELEX\u00ae<\/sup>, ALKINDI SPRINKLE\u00ae<\/sup>, DESMODA\u2122, GALZIN\u00ae<\/sup>, HEMANGEOL\u00ae<\/sup>, PKU GOLIKE\u00ae<\/sup>, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia\u00ae<\/sup>, ET-700, ET-800 and ZENEO\u00ae<\/sup> hydrocortisone autoinjector. For more information, please visit our website at\u00a0www.etonpharma.com<\/a>.<\/p>\n

\n Investor Relations:<\/strong>
\n
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the \u201cCompany\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith \u201cJudy\u201d M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026. The Company\u2019s current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement with Eton. \u201cWe … <\/p>\n

Continue reading “Eton Pharmaceuticals Announces CFO Succession Plan”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-951948","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEton Pharmaceuticals Announces CFO Succession Plan - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eton Pharmaceuticals Announces CFO Succession Plan - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the \u201cCompany\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith \u201cJudy\u201d M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026. The Company\u2019s current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement with Eton. \u201cWe … Continue reading "Eton Pharmaceuticals Announces CFO Succession Plan"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T11:11:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eton Pharmaceuticals Announces CFO Succession Plan\",\"datePublished\":\"2026-04-16T11:11:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/\"},\"wordCount\":426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/\",\"name\":\"Eton Pharmaceuticals Announces CFO Succession Plan - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=\",\"datePublished\":\"2026-04-16T11:11:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-cfo-succession-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eton Pharmaceuticals Announces CFO Succession Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eton Pharmaceuticals Announces CFO Succession Plan - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/","og_locale":"en_US","og_type":"article","og_title":"Eton Pharmaceuticals Announces CFO Succession Plan - Market Newsdesk","og_description":"Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc. (\u201cEton\u201d or the \u201cCompany\u201d) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith \u201cJudy\u201d M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026. The Company\u2019s current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement with Eton. \u201cWe … Continue reading \"Eton Pharmaceuticals Announces CFO Succession Plan\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-16T11:11:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eton Pharmaceuticals Announces CFO Succession Plan","datePublished":"2026-04-16T11:11:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/"},"wordCount":426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/","name":"Eton Pharmaceuticals Announces CFO Succession Plan - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=","datePublished":"2026-04-16T11:11:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MDgzOSM3NTM4MTM3IzIxMjI5ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-cfo-succession-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eton Pharmaceuticals Announces CFO Succession Plan"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=951948"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951948\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=951948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=951948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=951948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}